These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience. Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981 [No Abstract] [Full Text] [Related]
6. Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor. Wang X; Tang H; Bie Z; Wang Y; Yuan R; Zhang Z; Xiong Z; Yang Z; Bi Z; Wang B; Liu P Neurosurgery; 2024 Jan; ():. PubMed ID: 38289085 [TBL] [Abstract][Full Text] [Related]
7. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features. Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887 [TBL] [Abstract][Full Text] [Related]
8. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification. Dottermusch M; Schüller U; Hagel C; Saeger W Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335 [TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity. Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859 [TBL] [Abstract][Full Text] [Related]
10. Overview of the 2022 WHO Classification of Pituitary Tumors. Asa SL; Mete O; Perry A; Osamura RY Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028 [TBL] [Abstract][Full Text] [Related]
12. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version]. Xie J; Wu ZB Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420 [TBL] [Abstract][Full Text] [Related]
13. A Case of an Immature PIT1-Lineage Pituitary Neuroendocrine Tumor of the Nasopharynx. Peters J; Gryn O; Gerka-Stuyt J Cureus; 2023 Sep; 15(9):e44985. PubMed ID: 37701167 [TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset. Luo M; Tang R; Wang H J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134 [TBL] [Abstract][Full Text] [Related]
15. Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours. Lenders NF; Chui J; Low J; Inder WJ; Earls PE; McCormack AI Pituitary; 2022 Dec; 25(6):997-1003. PubMed ID: 36271964 [TBL] [Abstract][Full Text] [Related]
16. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia. Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436 [TBL] [Abstract][Full Text] [Related]
17. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902 [TBL] [Abstract][Full Text] [Related]
18. Practical approaches to diagnosing PitNETs/adenomas based on cell lineage. Goyal-Honavar A; Chacko G Brain Pathol; 2025 Jan; 35(1):e13298. PubMed ID: 39182926 [TBL] [Abstract][Full Text] [Related]
19. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies. Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537 [TBL] [Abstract][Full Text] [Related]
20. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. Zawada NB; Kunert-Radek J; Pawlikowski M; Pisarek H; Radek M Endokrynol Pol; 2016; 67(3):292-8. PubMed ID: 27345147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]